Future developments in the treatment of lung cancer

被引：0

作者：

Hirsch, FR ^{[1
]}

Fischer, JR ^{[1
]}

Niklinski, J ^{[1
]}

Zöchbaüer-Müller, S ^{[1
]}

机构：

[1] Univ Colorado, Ctr Canc, Dept Med Oncol Pathol, Denver, CO 80262 USA

来源：

LUNG CANCER | 2002年 / 38卷

关键词：

lung cancer; treatment; chemoprevention;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Lung cancer is the most frequent cause of cancer deaths in the western world. Despite some improvements in treatment results, especially by the use of combined treatment modalities, the overall prognosis is still very poor, and less than 15% of the patients survive 5-year after primary diagnosis. Through rapid developments in biotechnology and increased knowledge about important signaling pathways leading to cell proliferation, apoptosis, angiogenesis and metastases, new treatment possibilities with specific targeted therapies have emerged for chernoprevention and treatment of lung cancer. Together with developments of new technology available for early diagnosis new paradigms for management of lung cancer are under development with great promises for improvement of the overall prognosis. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.

引用

页码：S81 / S85

页数：5

共 24 条

[1]

Achiwa H, 1999, CLIN CANCER RES, V5, P1001

[2]

Adjei AA, 2000, CANCER RES, V60, P1871

[3] Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin [J].

Baselga, J ;

Pfister, D ;

Cooper, MR ;

Cohen, R ;

Burtness, B ;

Bos, M ;

D'Andrea, G ;

Seidman, A ;

Norton, L ;

Gunnett, K ;

Falcey, J ;

Anderson, V ;

Waksal, H ;

Mendelsohn, J .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (04) :904-914

[4]

Baylin SB, 1998, ADV CANCER RES, V72, P141

[5] Aberrant methylation of p16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis [J].

Belinsky, SA ;

Nikula, KJ ;

Palmisano, WA ;

Michels, R ;

Saccomanno, G ;

Gabrielson, E ;

Baylin, SB ;

Herman, JG .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (20) :11891-11896

[6]

BOS JL, 1989, CANCER RES, V49, P4682

[7]

Bunn PA, 2001, CLIN CANCER RES, V7, P3239

[8]

BUNN PA, 2001, TRANSLATION BIOL LUN, P391

[9] Epigenetic inactivation of RASSF14 in lung and breast cancers and malignant phenotype suppression [J].

Burbee, DG ;

Forgacs, E ;

Zöchbauer-Müller, S ;

Shivakumar, L ;

Fong, K ;

Gao, BN ;

Randle, D ;

Kondo, M ;

Virmani, A ;

Bader, S ;

Sekido, Y ;

Latif, F ;

Milchgrub, S ;

Toyooka, S ;

Gazdar, AF ;

Lerman, MI ;

Zabarovsky, E ;

White, M ;

Minna, JD .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (09) :691-699

[10] Anti-growth factor therapy for lung cancer [J].

Chan, DC ;

Geraci, M ;

Bunn, PA .

DRUG RESISTANCE UPDATES, 1998, 1 (06) :377-388

← 1 2 3 →